longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden 0.5 hours per response...

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	e Kesponses	/													
1. Name and Address of Reporting Person * Oron Assaf			2. Issuer Name and Ticker or Trading Symbol BiomX Inc. [PHGE]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director10% Owner						
(Last) (First) (Middle) C/O BIOMX LTD.,, 7 PINHAS SAPIR ST., FLOOR 2			` ´	3. Date of Earliest Transaction (Month/Day/Year) 03/30/2021					X	X Officer (give title below) Other (specify below)  Chief Business Officer					
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)						_X_	6. Individual or Joint/Group Filing(Check Applicable Line)  _X_Form filed by One Reporting Person  Form filed by More than One Reporting Person				
NESS ZIO	ONA,, L3	(State)	(Zip)			Tal	hla I	- Non-Dori	vativa Sacuritia	s Acquired	Dienosad	of or Rona	ficially Owner		
1.Title of Security 2. Transaction Date			2A. Deeme Execution I any (Month/Day		ned 3. Tra Code (Instr.		nsaction 4.	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)				neficially 6	7. of of orm:	Nature Indirect eneficial wnership	
						Cod	e V A	(A) or (D)	Price			(1	r Indirect (Indirect (Indi	nstr. 4)	
Reminder: F	ceport on a sc								s who respon orm are not r					a SEC 14.	74 (9-02)
Reminder: F	ceport on a si							in this f		equired to	respond	unless the		a SEC 14	/4 (9-02)
1. Title of	2. Conversion or Exercise Price of Derivative	3. Transaction Date		4. Transact	tion	5. Numb of Deriva Securitie Acquired or Dispos	er etive s	in this f display uired, Dispo options, co 6. Date Exe Expiration (Month/Da	orm are not rest a currently sed of, or Beneavertible securicisable and Date	equired to valid OMB	respond control n ned d Amount ring	unless the umber.  8. Price of	9. Number of Derivative Securities Beneficially Owned	10. Ownership Form of Derivative Security:	11. Natu
1. Title of Derivative Security	2. Conversion or Exercise Price of	3. Transaction Date	3A. Deemed Execution Date, if any	4. Transact	tion	5. Numb of Deriva Securitie Acquired	er ative s d (A) sed	in this f display uired, Dispo options, co 6. Date Exe Expiration (Month/Da	orm are not rest a currently sed of, or Beneavertible securicisable and Date	equired to valid OMB eficially Own ities)  7. Title and of Underly Securities	respond control n ned d Amount ring	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s	10. Ownership Form of Derivative Security: Direct (D) or Indirect	11. Natur of Indire Beneficia Ownersh
1. Title of Derivative Security	2. Conversion or Exercise Price of Derivative	3. Transaction Date	3A. Deemed Execution Date, if any	4. Transact	tion	Ils, warra 5. Numb of Deriva Securitie Acquired or Dispos of (D) (Instr. 3,	er ative s d (A) sed	in this f display uired, Dispo options, co 6. Date Exe Expiration (Month/Da	sed of, or Bendivertible security and Date y/Year)	equired to valid OMB eficially Own ities)  7. Title and of Underly Securities	respond control n ned d Amount ring	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported	10. Ownership Form of Derivative Security: Direct (D) or Indirect	11. Natur of Indire Beneficia Ownersh

## **Reporting Owners**

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Oron Assaf C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2 NESS ZIONA,, L3 7414002			Chief Business Officer			

## **Signatures**

/s/ Assaf Oron	04/01/2021
**Signature of Reporting Person	Date

# **Explanation of Responses:**

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The options vest and become exercisable over four years, with 25% of the shares subject to the option vesting on March 30, 2022, and the remainder vesting in 12 equal quarterly (1) installments over three years.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.